bad medical devices blog

Search

Topics

• Uncategorized

• Links

  • FDA


Case Review Form

* Denotes required field.

Title
Mr. Mrs. Ms. Miss Mr. & Mrs. Dr.

* First Name


* Last Name


* Email Address


* Phone Number


Cell Phone Number


Office Phone Number


Street Address


Apartment/Suite


City


State
-Choose State- Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington, D.C. West Virginia Wisconsin Wyoming -Puerto Rico- -U.S. Virgin Islands- -Other-

Zip Code


Please provide the best method and times to contact you:


Date of birth of injured person
(mm-dd-yyyy):


Name of medical device:


Please describe any problems or injuries caused by the device:


Other Info:


No Yes, I agree to the Parker & Waichman, LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker & Waichman, LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

• Archives

  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007

Latest Medical Device News

• 6 French Engage Introducer Devices by St. Jude Medical: Recall - Potential for Separation of Shaft From Hub - Potentially life threatening episode of bleeding could occur during surgical procedures.
• Combat Application Tourniquets (C-A-T): Suspected Counterfeit Product - Suspected counterfeit product is weaker, and breaks or bends before necessary force can be applied to stop blood flow. Excessive blood loss can endanger the victim’s life and ultimately lead to death.
• Cook brand Ciaglia Blue Rhino/Ciaglia Blue Dolphin Percutaneous Tracheostomy Introducer Sets and Trays - UPDATE 08/04/2010. Recall classified as Class I - balloon inflation assembly may not hold air. Originally posted 07/22/2010
• Fingerstick Devices to Obtain Blood Specimens: Initial Communication - Risk of Transmitting Bloodborne Pathogens - Increase in reports of bloodborne infection transmission resulting from the shared use of fingerstick and point-of-care blood testing devices.
• Huber Needles: Recall - Risk of Coring - Risk of infection, damage or death of tissue, swelling, or other serious adverse health consequences occurring as a result of the core travelling through blood vessels into the patient’s lungs.
• INOMAX DS Drug-Delivery System: Class I Recall - Risk of Interruption of Drug Flow - Potential for failure of a pressure switch, which may have an impact on the administration of INOMAX for inhalation to patients.
• Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use - Known long term risks associated with IVC filters include lower limb deep vein thrombosis, filter fracture, filter migration, filter embolization and IVC perforation.
• Lamictal (lamotrigine): Label Change - Risk of Aseptic Meningitis - Warnings and Precautions section of Prescribing Information and patient Medication Guide revised to include information about the risk of aseptic meningitis.
• MasXtreme Capsules (Natural Wellness) - product contains undeclared drug ingredient - UPDATED 08/25/2010. Product marketed as dietary supplement contains undeclared Aminotadalafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
• Midodrine hydrochloride: FDA Proposes Withdrawal of Low Blood Pressure Drug - Companies failed to provide evidence of clinical benefit of midodrine hydrochloride because required post-approval studies that verify the clinical benefit of the drug have not been done.
• Mr. Magic Male Enhancer: Undeclared Drug Ingredient - Product marketed as dietary supplement contains undeclared hydroxythiohomosildenafil and sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
• Novacare LLC Products: Recall - Undeclared Drug Ingredient - Products marketed as dietary supplement sexual enhancers for men contain undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.
• Octagam (Immune Globulin Intravenous (human)) 5% Liquid Preparation: Market Withdrawal - Risk of Thromboembolic Events - Customers asked to immediately quarantine the use of affected lots due to the potential for serious thromboembolic events.
• Prolatis’: Undeclared Drug Ingredient - Product marketed as dietary supplement contains undeclared sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
• Qualaquin (quinine sulfate): New Risk Evaluation and Mitigation Strategy - Risk of serious hematological reactions - UPDATE 08/04/2010. Dear Healthcare Professional Letter issued. New Risk Management Plan. Reports of serious side effects in patients using Qualaquin "off-label" for night time leg cramps. Originally posted 07/08/2010
• Revivexxx Extra Strength: Recall - Undeclared Drug Ingredient - Product marketed as a dietary supplement sexual enhancer for men contains undeclared tadalafil, which may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.
• Solo Slim, Solo Slim Extra Strength: Recall - Undeclared Drug Ingredient - Product contains undeclared didesmethyl sibutramine, which may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
• Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk - FDA evaluating clinical trial data that suggest patients taking drug may be at an increased risk for cardiovascular events compared to those taking carbidopa/levodopa
• TimeOut Capsules: Undeclared Drug Ingredient - Product marketed as dietary supplement contains undeclared hydroxythiohomosildenafil, a chemical similar to sildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
• Tygacil (tigecycline): Label Change - Increased Mortality Risk - Healthcare professionals should consider alternatives to Tygacil in patients with severe infections.

Archive for January, 2009

Copyright © 2010 bad medical devices blog | Entries and Comments